Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 22162909)


Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans.

Bogaard HJ, Mizuno S, Guignabert C, Al Hussaini AA, Farkas D, Ruiter G, Kraskauskas D, Fadel E, Allegood JC, Humbert M, Vonk Noordegraaf A, Spiegel S, Farkas L, Voelkel NF.

Am J Respir Cell Mol Biol. 2012 May;46(5):582-91. doi: 10.1165/rcmb.2011-0296OC. Epub 2011 Dec 28.


Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension.

Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM.

FASEB J. 2001 Feb;15(2):427-38.


Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.

Nave AH, Mižíková I, Niess G, Steenbock H, Reichenberger F, Talavera ML, Veit F, Herold S, Mayer K, Vadász I, Weissmann N, Seeger W, Brinckmann J, Morty RE.

Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1446-58. doi: 10.1161/ATVBAHA.114.303534. Epub 2014 May 15.


Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.

Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, Lauzon-Joset JF, Breuils-Bonnet S, Tremblay É, Biardel S, Racine C, Courture C, Bonnet P, Majka SM, Deshaies Y, Picard F, Provencher S, Bonnet S.

J Am Heart Assoc. 2013 Jan 16;2(1):e005157. doi: 10.1161/JAHA.112.005157.


Thyroid hormone is highly permissive in angioproliferative pulmonary hypertension in rats.

Al Husseini A, Bagnato G, Farkas L, Gomez-Arroyo J, Farkas D, Mizuno S, Kraskauskas D, Abbate A, Van Tassel B, Voelkel NF, Bogaard HJ.

Eur Respir J. 2013 Jan;41(1):104-14. doi: 10.1183/09031936.00196511. Epub 2012 Jul 26.


Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling.

Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C, Wood K, Parr JE, Boackle SA, Voelkel NF.

Am J Respir Crit Care Med. 2007 Jun 15;175(12):1280-9. Epub 2007 Apr 5.


Role of Src tyrosine kinases in experimental pulmonary hypertension.

Pullamsetti SS, Berghausen EM, Dabral S, Tretyn A, Butrous E, Savai R, Butrous G, Dahal BK, Brandes RP, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Rosenkranz S, Schermuly RT.

Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1354-65. doi: 10.1161/ATVBAHA.112.248500. Epub 2012 Apr 19.


Bortezomib alleviates experimental pulmonary arterial hypertension.

Kim SY, Lee JH, Huh JW, Kim HJ, Park MK, Ro JY, Oh YM, Lee SD, Lee YS.

Am J Respir Cell Mol Biol. 2012 Nov;47(5):698-708. doi: 10.1165/rcmb.2011-0331OC. Epub 2012 Jul 27.


Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension.

Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, Burns N, Kasper M, Voelkel NF.

Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L668-76. Epub 2006 May 12.


Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation.

Zuckerbraun BS, Shiva S, Ifedigbo E, Mathier MA, Mollen KP, Rao J, Bauer PM, Choi JJ, Curtis E, Choi AM, Gladwin MT.

Circulation. 2010 Jan 5;121(1):98-109. doi: 10.1161/CIRCULATIONAHA.109.891077. Epub 2009 Dec 21.


Endothelial progenitor cells may inhibit apoptosis of pulmonary microvascular endothelial cells: new insights into cell therapy for pulmonary arterial hypertension.

Xia L, Fu GS, Yang JX, Zhang FR, Wang XX.

Cytotherapy. 2009;11(4):492-502. doi: 10.1080/14653240902960460.


Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.

Mizuno S, Farkas L, Al Husseini A, Farkas D, Gomez-Arroyo J, Kraskauskas D, Nicolls MR, Cool CD, Bogaard HJ, Voelkel NF.

Am J Respir Cell Mol Biol. 2012 Nov;47(5):679-87. doi: 10.1165/rcmb.2012-0077OC. Epub 2012 Jul 27.


Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung.

Sands M, Howell K, Costello CM, McLoughlin P.

Respir Res. 2011 Jan 25;12:17. doi: 10.1186/1465-9921-12-17.


Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing.

Ibrahim YF, Wong CM, Pavlickova L, Liu L, Trasar L, Bansal G, Suzuki YJ.

J Am Heart Assoc. 2014 Feb 26;3(1):e000520. doi: 10.1161/JAHA.113.000520.


Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension.

Derrett-Smith EC, Dooley A, Gilbane AJ, Trinder SL, Khan K, Baliga R, Holmes AM, Hobbs AJ, Abraham D, Denton CP.

Arthritis Rheum. 2013 Nov;65(11):2928-39. doi: 10.1002/art.38078.


Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension.

Alzoubi A, Toba M, Abe K, O'Neill KD, Rocic P, Fagan KA, McMurtry IF, Oka M.

Am J Physiol Heart Circ Physiol. 2013 Jun 15;304(12):H1708-18. doi: 10.1152/ajpheart.00746.2012. Epub 2013 Apr 12.


VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats.

Farkas L, Farkas D, Ask K, Möller A, Gauldie J, Margetts P, Inman M, Kolb M.

J Clin Invest. 2009 May;119(5):1298-311. doi: 10.1172/JCI36136. Epub 2009 Apr 20.


The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.

Rakotoniaina Z, Guerard P, Lirussi F, Goirand F, Rochette L, Dumas M, Bardou M.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Dec;374(3):195-206. Epub 2006 Nov 11.


CXCR4 inhibition ameliorates severe obliterative pulmonary hypertension and accumulation of C-kit⁺ cells in rats.

Farkas D, Kraskauskas D, Drake JI, Alhussaini AA, Kraskauskiene V, Bogaard HJ, Cool CD, Voelkel NF, Farkas L.

PLoS One. 2014 Feb 24;9(2):e89810. doi: 10.1371/journal.pone.0089810. eCollection 2014.


Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure.

Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH.

Am J Physiol Lung Cell Mol Physiol. 2002 Sep;283(3):L555-62.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk